JP2001514858A5 - - Google Patents

Download PDF

Info

Publication number
JP2001514858A5
JP2001514858A5 JP2000508817A JP2000508817A JP2001514858A5 JP 2001514858 A5 JP2001514858 A5 JP 2001514858A5 JP 2000508817 A JP2000508817 A JP 2000508817A JP 2000508817 A JP2000508817 A JP 2000508817A JP 2001514858 A5 JP2001514858 A5 JP 2001514858A5
Authority
JP
Japan
Prior art keywords
conjugate
region
protein
host cell
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000508817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514858A (ja
Filing date
Publication date
Priority claimed from GBGB9718609.2A external-priority patent/GB9718609D0/en
Application filed filed Critical
Publication of JP2001514858A publication Critical patent/JP2001514858A/ja
Publication of JP2001514858A5 publication Critical patent/JP2001514858A5/ja
Pending legal-status Critical Current

Links

JP2000508817A 1997-09-02 1998-09-02 アンテナペディアのホメオドメインを含むコンジュゲート Pending JP2001514858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
GB9718609.2 1997-09-02
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia

Publications (2)

Publication Number Publication Date
JP2001514858A JP2001514858A (ja) 2001-09-18
JP2001514858A5 true JP2001514858A5 (enExample) 2006-01-05

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000508817A Pending JP2001514858A (ja) 1997-09-02 1998-09-02 アンテナペディアのホメオドメインを含むコンジュゲート

Country Status (10)

Country Link
US (2) US7968512B2 (enExample)
EP (1) EP1009847A1 (enExample)
JP (1) JP2001514858A (enExample)
AU (1) AU737829B2 (enExample)
BR (1) BR9811744A (enExample)
CA (1) CA2301157A1 (enExample)
GB (1) GB9718609D0 (enExample)
IL (2) IL134602A0 (enExample)
NZ (1) NZ503007A (enExample)
WO (1) WO1999011809A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273192A1 (en) * 1996-12-02 1998-06-11 Wake Forest University Inactivation of hiv co-receptors as therapy for hiv infection
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
EP1140202A1 (en) 1998-12-24 2001-10-10 Ucb S.A. Peptidic product, process and composition
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
WO2002020737A2 (en) * 2000-09-07 2002-03-14 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
WO2002098365A2 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
AU2010238346A1 (en) 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012154684A2 (en) * 2011-05-06 2012-11-15 University Of Rochester Method of preventing development of psoriatic lesions
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
CA3233345A1 (en) 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
RU2708375C2 (ru) 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CA3020344A1 (en) 2016-04-07 2017-10-12 Case Western Reserve University Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
AU2018301399B2 (en) 2017-07-11 2024-08-29 Case Western Reserve University Compositions and methods for treating myelin disorders
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Similar Documents

Publication Publication Date Title
JP2023506765A5 (enExample)
JP2002527052A5 (enExample)
JP2004503213A5 (enExample)
JP2008505985A5 (enExample)
JP2003503366A5 (enExample)
WO1996004385A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP2003510366A5 (enExample)
WO2006056464A3 (en) Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
JPH07506821A (ja) ジフテリア毒素受容体結合領域
JPH11253181A (ja) 組換えシュードモナスエクソトキシン:低副作用の活性イムノトキシンの構造
WO2003046560B1 (en) Self-assembly molecules
JP2023538422A5 (enExample)
JP2008507298A5 (enExample)
WO2013036973A2 (en) Methods and compositions for controlling assembly of viral proteins
JP2004515575A5 (enExample)
JP2001526242A5 (enExample)
CA2311648A1 (en) Ifnar2/ifn complex
CA2392202A1 (en) Constructs for delivery of therapeutic agents to neuronal cells
WO2003051912A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP2009507503A5 (enExample)
CN115057938A (zh) 抗新型冠状病毒人源化多价结合蛋白及其应用
JP2023550287A5 (enExample)
AU704594B2 (en) Production of recombinant peptides as natural hydrophobic peptide analogues
JPS6299399A (ja) ヒトγ−インタ−フエロンの生物活性誘導体
KR920012440A (ko) 인간 인터류킨-5 수용체